414 related articles for article (PubMed ID: 17804742)
1. Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin.
Son YG; Kim EH; Kim JY; Kim SU; Kwon TK; Yoon AR; Yun CO; Choi KS
Cancer Res; 2007 Sep; 67(17):8274-84. PubMed ID: 17804742
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation.
Kim EH; Yoon MJ; Kim SU; Kwon TK; Sohn S; Choi KS
Cancer Res; 2008 Jan; 68(1):266-75. PubMed ID: 18172319
[TBL] [Abstract][Full Text] [Related]
3. Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPS down-regulation.
Kim JY; Kim EH; Park SS; Lim JH; Kwon TK; Choi KS
J Cell Biochem; 2008 Dec; 105(6):1386-98. PubMed ID: 18980244
[TBL] [Abstract][Full Text] [Related]
4. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
5. Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.
Lee TJ; Um HJ; Min do S; Park JW; Choi KS; Kwon TK
Free Radic Biol Med; 2009 Jun; 46(12):1639-49. PubMed ID: 19345731
[TBL] [Abstract][Full Text] [Related]
6. Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP.
Kim EH; Kim SU; Choi KS
Oncogene; 2005 Jan; 24(5):838-49. PubMed ID: 15531913
[TBL] [Abstract][Full Text] [Related]
7. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY
Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158
[TBL] [Abstract][Full Text] [Related]
8. Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin.
Schultze K; Böck B; Eckert A; Oevermann L; Ramacher D; Wiestler O; Roth W
Apoptosis; 2006 Sep; 11(9):1503-12. PubMed ID: 16820965
[TBL] [Abstract][Full Text] [Related]
9. The XIAP inhibitor Embelin enhances TRAIL-mediated apoptosis in malignant glioma cells by down-regulation of the short isoform of FLIP.
Siegelin MD; Gaiser T; Siegelin Y
Neurochem Int; 2009 Nov; 55(6):423-30. PubMed ID: 19409438
[TBL] [Abstract][Full Text] [Related]
10. Myricetin sensitizes malignant glioma cells to TRAIL-mediated apoptosis by down-regulation of the short isoform of FLIP and bcl-2.
Siegelin MD; Gaiser T; Habel A; Siegelin Y
Cancer Lett; 2009 Oct; 283(2):230-8. PubMed ID: 19398149
[TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.
Kim YH; Jung EM; Lee TJ; Kim SH; Choi YH; Park JW; Park JW; Choi KS; Kwon TK
Free Radic Biol Med; 2008 Mar; 44(6):1055-68. PubMed ID: 18164688
[TBL] [Abstract][Full Text] [Related]
12. Capsaicin sensitizes malignant glioma cells to TRAIL-mediated apoptosis via DR5 upregulation and survivin downregulation.
Kim JY; Kim EH; Kim SU; Kwon TK; Choi KS
Carcinogenesis; 2010 Mar; 31(3):367-75. PubMed ID: 19939880
[TBL] [Abstract][Full Text] [Related]
13. Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP.
Kim EH; Kim HS; Kim SU; Noh EJ; Lee JS; Choi KS
Oncogene; 2005 Oct; 24(46):6877-89. PubMed ID: 16007142
[TBL] [Abstract][Full Text] [Related]
14. The flavonolignan silibinin potentiates TRAIL-induced apoptosis in human colon adenocarcinoma and in derived TRAIL-resistant metastatic cells.
Kauntz H; Bousserouel S; Gossé F; Raul F
Apoptosis; 2012 Aug; 17(8):797-809. PubMed ID: 22555452
[TBL] [Abstract][Full Text] [Related]
15. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand.
Yasuda T; Yoshida T; Goda AE; Horinaka M; Yano K; Shiraishi T; Wakada M; Mizutani Y; Miki T; Sakai T
Mol Cancer Res; 2008 Dec; 6(12):1852-60. PubMed ID: 19074830
[TBL] [Abstract][Full Text] [Related]
16. Genistein enhances proteasomal degradation of the short isoform of FLIP in malignant glioma cells and thereby augments TRAIL-mediated apoptosis.
Siegelin MD; Siegelin Y; Habel A; Gaiser T
Neurosci Lett; 2009 Apr; 453(2):92-7. PubMed ID: 19356600
[TBL] [Abstract][Full Text] [Related]
17. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis.
Hetschko H; Voss V; Seifert V; Prehn JH; Kögel D
FEBS J; 2008 Apr; 275(8):1925-36. PubMed ID: 18341587
[TBL] [Abstract][Full Text] [Related]
19. Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma.
Siegelin MD; Habel A; Gaiser T
Neurosci Lett; 2008 Dec; 448(1):161-5. PubMed ID: 18948169
[TBL] [Abstract][Full Text] [Related]
20. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation.
Shigeno M; Nakao K; Ichikawa T; Suzuki K; Kawakami A; Abiru S; Miyazoe S; Nakagawa Y; Ishikawa H; Hamasaki K; Nakata K; Ishii N; Eguchi K
Oncogene; 2003 Mar; 22(11):1653-62. PubMed ID: 12642868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
